Skip to main content
SpringerLink
Log in

Timing and Protocols of Clinical and Endoscopic Surveillance of Barrett’s Esophagus

  • Chapter
  • First Online:
Revisiting Barrett's Esophagus

  • 518 Accesses

Abstract

There has been a rapid increase in the incidence of esophageal adenocarcinoma in most Western countries over the past 30 years. Barrett’s esophagus (BE) is a common premalignant lesion of esophageal adenocarcinoma although the risk of developing cancer in BE remains low. Therefore, screening is not recommended in the general population. Surveillance of BE is recommended to detect high-grade dysplasia or carcinoma in an earlystage although there is no clear evidence that surveillance leads to a reduced mortality. This chapter discusses the time and protocols of clinical and endoscopic surveillance.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Fitzgerald RC, di Pietro M, Ragunath K, Ang Y, Kang JY, Watson P, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63:7–42.

    Article  PubMed Central  Google Scholar 

  2. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ, American Gastroenterological A. American Gastroenterological Association technical review on the management of Barrett’s esophagus. Gastroenterology. 2011;140:18–52.

    Article  Google Scholar 

  3. Bennett C, Vakil N, Bergman J, Harrison R, Odze R, Vieth M, et al. Consensus statements for management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology. 2012;143:336–46.

    Article  PubMed Central  Google Scholar 

  4. Das D, Chilton AP, Jankowski JA. Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res. 2009;181:161–9.

    Article  CAS  PubMed Central  Google Scholar 

  5. Jankowski J, Barr H, Wang K, Delaney B. Diagnosis and management of Barrett’s oesophagus. BMJ. 2010;341:c4551.

    Article  PubMed Central  Google Scholar 

  6. Jankowski J, Barr H. Improving surveillance for Barrett’s oesophagus: AspECT and BOSS trials provide an evidence base. BMJ. 2006;332(7556):1512.

    Article  PubMed Central  Google Scholar 

  7. Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129:1825–31.

    Article  Google Scholar 

  8. Ford AC, Forman D, Reynolds PD, Cooper BT, Moayyedi P. Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett’s esophagus. Am J Epidemiol. 2005;162:454–60.

    Article  Google Scholar 

  9. Malfertheiner P, Lind T, Willich S, Vieth M, Jaspersen D, Labenz J, et al. Prognostic influence of Barrett’s oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study. Gut. 2005;54:746–51.

    Article  CAS  PubMed Central  Google Scholar 

  10. Coleman HG, Bhat S, Murray LJ, McManus D, Gavin AT, Johnston BT. Increasing incidence of Barrett’s oesophagus: a population-based study. Eur J Epidemiol. 2011;26:739–45.

    Article  PubMed Central  Google Scholar 

  11. Taylor JB, Rubenstein JH. Meta-analyses of the effect of symptoms of gastroesophageal reflux on the risk of Barrett’s esophagus. Am J Gastroenterol. 2010;105:1729–37.

    Article  PubMed Central  Google Scholar 

  12. Ronkainen J, Talley NJ, Storskrubb T, Johansson SE, Lind T, Vieth M, et al. Erosive esophagitis is a risk factor for Barrett’s esophagus: a community-based endoscopic follow-up study. Am J Gastroenterol. 2011;106:1946–52.

    Article  PubMed Central  Google Scholar 

  13. Erichsen R, Robertson D, Farkas DK, Pedersen L, Pohl H, Baron JA, et al. Erosive reflux disease increases risk for esophageal adenocarcinoma, compared with nonerosive reflux. Clin Gastroenterol Hepatol. 2012;10:475–80.

    Article  PubMed Central  Google Scholar 

  14. Malfertheiner P, Nocon M, Vieth M, Stolte M, Jaspersen D, Koelz HR, et al. Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care--the ProGERD study. Aliment Pharmacol Ther. 2012;35:154–64.

    Article  CAS  PubMed Central  Google Scholar 

  15. Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma. CA Cancer J Clin. 2013;63:232–48.

    Article  PubMed Central  Google Scholar 

  16. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.

    Article  PubMed Central  Google Scholar 

  17. Solaymani-Dodaran M, Card TR, West J. Cause-specific mortality of people with Barrett’s esophagus compared with the general population: a population-based cohort study. Gastroenterology. 2013;144:1375–83.

    Article  PubMed Central  Google Scholar 

  18. Anderson LA, Murray LJ, Murphy SJ, et al. Mortality in Barrett’s oesophagus: results from a population based study. Gut. 2003;52:1081–4.

    Article  CAS  PubMed Central  Google Scholar 

  19. Bennett C, Moayyedi P, Corley DA, Den Caestecker J, Falck-Ytter Y, Falk G, et al. BOB CAT: a large-scale review and Delphi consensus for management of Barrett’s esophagus with No Dysplasia, indefinite for, or low-grade Dysplasia. Am J Gastroenterol. 2015;110:662–82.

    Article  PubMed Central  Google Scholar 

  20. Evans J, Early D, Fukami N, Ben-Menachem T, Chandrasekhara V, Chathadi K, et al. The role of endoscopy in Barrett’s esophagus and other premalignant conditions of the esophagus. Gastrointest Endosc. 2012;76:1087–94.

    Article  PubMed Central  Google Scholar 

  21. Shaheen NJ, Falk GW, Iyer PG, Gerson L. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2015;111:30–50.

    Article  PubMed Central  Google Scholar 

  22. American Gastroenterological Association, Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American gastroenterological association medical position statement on the management of Barrett’s esophagus. Gastroenterology. 2011;140:1084–91.

    Article  Google Scholar 

  23. Sikkema M, Looman CW, Steyerberg EW, Kerkhof M, Kastelein F, van Dekken H, et al. Predictors for neoplastic progression in patients with Barrett’s Esophagus: a prospective cohort study. Am J Gastroenterol. 2011;106:1231–8.

    Article  CAS  PubMed Central  Google Scholar 

  24. Phoa KN, van Vilsteren FG, Weusten BL, Bisschops R, Schoon EJ, Ragunath K, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014;311:1209–17.

    Article  CAS  PubMed Central  Google Scholar 

  25. Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011;103:1049–57.

    Article  PubMed Central  Google Scholar 

  26. Nunobe S, Nakanishi Y, Taniguchi H, et al. Two distinct pathways of tumorigenesis of adenocarcinomas of the esophagogastric junction, related or unrelated to intestinal metaplasia. Pathol Int. 2007;57:315–21.

    Article  CAS  PubMed Central  Google Scholar 

  27. Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365:1375–83.

    Article  CAS  Google Scholar 

  28. Bisschops R. Optimal endoluminal treatment of Barrett’s esophagus: integrating novel strategies into clinical practice. Expert Rev Gastroenterol Hepatol. 2010;4:319–33.

    Article  Google Scholar 

  29. Fountoulakis A, Zafirellis KD, Dolan K, Dexter SPL, Martin IG, Sue-Ling HM. Effect of surveillance of Barrett’s oesophagus on the clinical outcome of oesophageal cancer. Br J Surg. 2004;91:997–1003.

    Article  CAS  Google Scholar 

  30. Lerut T, Coosemans W, Van Raemdonck D, Dillemans B, De Leyn P, Marnette JM, et al. Surgical treatment of Barrett’s carcinoma. Correlations between morphologic findings and prognosis. J Thorac Cardiovasc Surg. 1994;107:1059–65.

    CAS  PubMed  Google Scholar 

  31. Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE, et al. Dysplasia and Cancer in a large multicenter cohort of patients with Barrett’s Esophagus. Clin Gastroenterol Hepatol. 2006;4:566–72.

    Article  PubMed Central  Google Scholar 

  32. Sharma P. Barrett’s esophagus. N Engl J Med. 2009;26361:2548–56.

    Article  Google Scholar 

  33. Kastelein F, van Olphen S, Steyerberg EW, Sikkema M, Spaander MCW, Looman CWN, et al. Surveillance in patients with long-segment Barrett’s oesophagus: a cost-effectiveness analysis. Gut. 2015;64:864–71.

    Article  CAS  PubMed Central  Google Scholar 

  34. Rubenstein JH, Scheiman JM, Sadeghi S, Whiteman D, Inadomi JM. Esophageal adenocarcinoma incidence in individuals with gastroesophageal reflux: synthesis and estimates from population studies. Am J Gastroenterol. 2011;106:254–60.

    Article  PubMed Central  Google Scholar 

  35. Provenzale D, Schmitt C, Wong JB. Barrett’s esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol. 1999;94:2043–53.

    Article  CAS  PubMed Central  Google Scholar 

  36. Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA, McKinney A, et al. Surveillance and survival in Barrett’s adenocarcinomas: a population-based study. Gastroenterology. 2002;122:633–40.

    Article  PubMed Central  Google Scholar 

  37. Hu Q, Sun T-T, Hong J, Fang J-Y, Xiong H, Meltzer SJ. Proton pump inhibitors do not reduce the risk of esophageal adenocarcinoma in patients with Barrett’s esophagus: a systematic review and meta-analysis. PLoS One. 2017;12:e0169691.

    Article  PubMed Central  Google Scholar 

  38. Singh S, Garg SK, Singh PP, Iyer PG, El-Serag HB. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett’s oesophagus: a systematic review and meta-analysis. Gut. 2014;63:1229–37.

    Article  PubMed Central  Google Scholar 

  39. Levine DS, Blount PL, Rudolph RE, et al. Safety of a systematic endoscopic biopsy protocol in patients with Barrett’s esophagus. Am J Gastroenterol. 2000;95:1152–7.

    Article  CAS  PubMed Central  Google Scholar 

  40. Ross-Innes CS, Debiram-Beecham I, O’Donovan M, Walker E, Varghese S, Lao-Sirieix P, et al. Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett’s esophagus: a multi-center case-control study. PLoS Med. 2015;12:1–19.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine and Surgery, University Alma Mater Bologna, Italy—School of Medicine, Bologna, Italy

    Carlo Calabrese, Marco Salice & Fernando Rizzello

  2. Gastroenterology and Digestive Endoscopy Unit, Department of Medical and Surgical Sciences (DIMEC), University Alma Mater Bologna, Italy—School of Medicine, Bologna, Italy

    Nico Pagano

  3. Gastroenterology and Digestive Endoscopy Unit, NOCSAE Hospital of Modena, Modena, Italy

    Raffaele Manta

Authors
  1. Carlo Calabrese
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marco Salice
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nico Pagano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Raffaele Manta
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fernando Rizzello
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carlo Calabrese .

Editor information

Editors and Affiliations

  1. Department of Clinical Medicine and Surgery, University of Naples Federico II, School of Medicine, Naples, Italy

    Giuseppe Galloro

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Calabrese, C., Salice, M., Pagano, N., Manta, R., Rizzello, F. (2019). Timing and Protocols of Clinical and Endoscopic Surveillance of Barrett’s Esophagus. In: Galloro, G. (eds) Revisiting Barrett's Esophagus. Springer, Cham. https://doi.org/10.1007/978-3-319-92093-1_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-92093-1_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-92092-4

  • Online ISBN: 978-3-319-92093-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation